Summary & Overview
CPT 0398U: ESOPREDICT® Barrett’s Esophagus Risk Classifier Assay
Headline: New PLA CPT code 0398U designates ESOPREDICT® assay for Barrett’s esophagus progression risk. Lead: CPT code 0398U identifies a proprietary molecular diagnostic assay that evaluates methylation in esophageal FFPE biopsy samples and reports a risk score for progression to high-grade dysplasia or esophageal cancer. This code formalizes billing for a single-manufacturer test and has implications for coverage and utilization of advanced genomic risk stratification.
CPT code 0398U represents a Proprietary Laboratory Analyses (PLA) code tied to a single, manufacturer-specific test: the ESOPREDICT® Barrett’s Esophagus Risk Classifier Assay from Capsulomics Inc. d/b/a Previse. The test matters nationally as adoption of precision molecular diagnostics influences surveillance strategies for patients with Barrett’s esophagus and may affect laboratory billing patterns and payer coverage policies. Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will learn the clinical context of the assay, typical service setting, and the nature of PLA coding. The publication summarizes payer coverage scope, common modifiers observed with laboratory services, and expected service-line placement. It also outlines benchmarking considerations and policy implications for proprietary molecular tests. Data not available in the input is noted where applicable, and the focus remains on national policy and billing context rather than specific recommendations.
Billing Code Overview
CPT code 0398U is a Proprietary Laboratory Analyses (PLA) code for the ESOPREDICT® Barrett’s Esophagus Risk Classifier Assay from Capsulomics Inc. d/b/a Previse. The test analyzes methylation status of specific genes using esophageal cells obtained from a formalin–fixed paraffin–embedded (FFPE) biopsy specimen and reports an algorithm-derived risk score for progression to high-grade dysplasia or esophageal cancer.
-
Service type: Laboratory molecular diagnostic assay (proprietary PLA test)
-
Typical site of service: Clinical laboratory processing FFPE biopsy specimens; specimen collection occurs in outpatient endoscopy or surgical biopsy settings where esophageal tissue is obtained.
Clinical & Coding Specifications
Clinical Context
A 58-year-old patient with a long-standing history of gastroesophageal reflux disease (GERD) undergoes endoscopic surveillance after prior biopsy-proven Barrett’s esophagus. An endoscopic biopsy of the distal esophagus is fixed in formalin and embedded in paraffin (FFPE) by the pathology lab. Tissue sections are sent to a CAP/CLIA-certified reference laboratory performing the ESOPREDICT® Barrett’s Esophagus Risk Classifier Assay (0398U). The laboratory performs methylation analysis on targeted genes from the FFPE specimen and runs an algorithmic risk model to generate a risk score for progression to high-grade dysplasia or esophageal adenocarcinoma. Results are transmitted to the ordering gastroenterologist and incorporated into the patient’s longitudinal risk stratification and surveillance planning. Typical sites of service include ambulatory surgery centers, hospital outpatient departments, and independent clinical laboratories that receive FFPE biopsy specimens. The service type is laboratory-based molecular diagnostic testing performed by a proprietary assay; the specimen collection was performed during an upper endoscopy by a gastroenterology provider and the analytic testing and reporting are performed by the manufacturer-specific laboratory.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when reporting only the professional interpretation component provided by the performing laboratory or pathologist separate from technical processing. |
TC | Technical component | Use when reporting only the technical component of the laboratory test (analytic processing, equipment, and technician time). |
QK | CLIA waived test performed at point of care (Phlebotomy/Provider-site) | Rarely applicable; use only if a component of specimen handling meets CLIA-defined point-of-care reporting requirements linked to payer rules. |
QX | Modifier for CLIA-waived test performed by a non-laboratory practitioner | As above, use only per payer/CLIA guidance when non-lab practitioner performed waived test components. |
QY | Laboratory test performed by a physician or nonphysician practitioner | Use when the provider’s office (non-referenced lab) performs testing under physician supervision per payer rules. |
52 | Reduced services | Use when specimen or testing is partial or limited (for example, incomplete analysis due to insufficient tissue). |
53 | Discontinued procedure | Use if test processing was started but discontinued for documented clinical reasons (e.g., inadequate specimen, contamination). |
22 | Increased procedural services | Use when work, time, or resources materially exceed typical test complexity and documentation supports substantial additional effort. |
78 | Unplanned return to the operating/procedure room by the same physician following initial procedure | Use only if a diagnostic or therapeutic endoscopic re-intervention occurred relating to the same episode; not typically appended to laboratory PLA codes but included for completeness when workflow spans procedures. |
80 | Assistant surgeon | Use when an assistant surgeon participated in the endoscopic biopsy procedure that provided the FFPE specimen, for facility billing of the surgical encounter (not appended to the PLA code itself). |
62 | Two surgeons | Use when two surgeons share the operative procedure (applies to the biopsy procedural claim, not to the laboratory PLA code). |
AS | Physician assistant, nurse practitioner, or clinical nurse specialist services for assistant at surgery | Use where applicable to the procedural encounter that generated the specimen; not appended to the laboratory PLA code. |
QY | (listed again above) | (See prior QY entry.) |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
| 208000000X | Gastroenterology | Gastroenterologists perform the endoscopic biopsy that provides the FFPE specimen. |
| 207L00000X | Pathology | Pathologists review biopsy specimens, may coordinate specimen submission and initial histology. |
| 334M00000X | Molecular Pathology | Molecular pathologists or molecular diagnostics laboratories perform and interpret methylation assays. |
| 363L00000X | Clinical Laboratory | Clinical laboratory professionals and directors manage the analytic testing and CLIA processes for the proprietary assay. |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
K22.7 | Barrett esophagus | Primary indication for performing risk stratification with the ESOPREDICT® methylation assay to assess progression risk. |
K21.9 | Gastro-esophageal reflux disease without esophagitis | Common underlying condition associated with development of Barrett esophagus and reason for surveillance. |
R12 | Heartburn | Symptom prompting evaluation and surveillance endoscopy that may yield biopsy for molecular testing. |
K22.8 | Other specified diseases of esophagus | Used when other esophageal pathology coexists and molecular risk stratification is considered. |
C15.9 | Malignant neoplasm of esophagus, unspecified | Relevant for prior history or differential diagnosis when assessing risk of progression to esophageal cancer. |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
43235 | Esophagogastroduodenoscopy, flexible, transoral; diagnostic, with or without collection of specimen by brushing or washing | Performs diagnostic upper endoscopy and may include biopsy collection that yields the FFPE specimen used for 0398U. |
43239 | Esophagogastroduodenoscopy with biopsy, single or multiple | Common procedural code for obtaining mucosal biopsies of the esophagus; provides the tissue required for the methylation assay reported with 0398U. |
88305 | Level IV surgical pathology, gross and microscopic examination | Initial histopathologic evaluation of the endoscopic biopsy; often accompanies the workflow prior to sending tissue for specialized molecular testing. |
88172 | Cytopathology, smears, or other preparatory procedures for cytologic examination (when applicable) | Used if additional cytology preparations are performed from biopsy or brushings prior to molecular testing. |
86152 | Antibody or antigens; immunoassay for tumor markers (example) | Represents ancillary laboratory testing that may be ordered in parallel; not specific to methylation assay but may appear in the diagnostic workup. |